Myriad raises price of BRCA testing, again.

On April 1, 2010 - three days after a court ruling that invalidated Myriad's patents on the BRCA1 and BRCA2 genes (associated with hereditary breast and ovarian cancer) the company increased their prices for genetic testing. Old cost =$3,770. New cost = $4,040 for full sequencing plus rearrangement testing.

Read more!

Congratulations to Christina Appelgate!

Congratulations to Christina Applegate on her recent engagement! Christina was diagnosed with breast cancer at age 36, and learned that she carries a BRCA1 mutation and chose to have a bilateral mastectomy with reconstruction. She reports that her fiancé has been "incredible" through her diagnosis and surgery. Follow the light blue link above to hear Christina's interview on Access Hollywood about breast reconstruction. Read more!

The latest version of Cancer Bytes is now available!

Check out the latest version of Cancer Bytes: Straight Talk about Early-Onset Ovarian Cancer. Click on the above light blue link to listen to this interview.

Read more!

Should our genes be patented?

Myriad’s patents on the BRCA genes (associated with hereditary breast and ovarian cancer) include a sequence of DNA that is found in millions of other locations in the genome. Anyone making, using, selling, or importing this segment is in violation of these patents. Upon inspection, these patents appear to be surprisingly broad, and if enforced would have substantial implications for medical practice and scientific research. What do you think: should our genes be patented? Read more!

"A Body Resculpted"

Click on the above light blue link to read Ms. Freedman Roth's intimate essay entitled "A Body Resculpted" about her journey through breast surgery and reconstruction. Read more!

In Depth Report on Gene Patenting

Follow the above light blue link to view CBS's 60 Minutes segment on gene patenting and what the ACLU is doing to ensure no one can patent your genes!

Read more!

Gene Patenting Featured on 60 Minutes

60 Minutes examines the idea of biotech firms patenting genes for profit! Tune in on Sunday, April 4th at 7 pm. Click the above light blue link to see a preview. Read more!

Patents On Breast Cancer Genes Ruled Invalid

The patents on the BRCA1 and BRCA2 genes, associated with hereditary breast and ovarian cancer, were ruled invalid in a New York federal court yesterday. The precedent-setting ruling marks the first time a court has found patents on genes unlawful.

Please click on the above light blue link to be directed to the New York Times article.

Please see below for the full press release from the ACLU.

FOR IMMEDIATE RELEASE

March 29, 2010

CONTACT: Maria Archuleta, (917) 892-9180 or (212) 549-2689 or 2666; media@aclu.org

NEW YORK – Patents on genes associated with hereditary breast and ovarian cancer are invalid, ruled a New York federal court today. The precedent-setting ruling marks the first time a court has found patents on genes unlawful and calls into question the validity of patents now held on approximately 2000 human genes. The ruling follows a lawsuit brought by a group of patients and scientists represented by the American Civil Liberties Union and the Public Patent Foundation (PUBPAT), a not-for-profit organization affiliated with Benjamin N. Cardozo School of Law.

"Today's ruling is a victory for the free flow of ideas in scientific research," said Chris Hansen, a staff attorney with the ACLU First Amendment Working Group. "The human genome, like the structure of blood, air or water, was discovered, not created. There is an endless amount of information on genes that begs for further discovery, and gene patents put up unacceptable barriers to the free exchange of ideas."

The ACLU's and PUBPAT's lawsuit against Myriad Genetics and the University of Utah Research Foundation, which hold the patents on the BRCA genes, as well the U.S. Patent and Trademark Office (USPTO), charged that the challenged patents are illegal and restrict both scientific research and patients' access to medical care, and that patents on human genes violate the First Amendment and patent law because genes are "products of nature."

The court today granted the U.S. Patent and Trademark Office's (USPTO) request that it be released as a defendant in the lawsuit. The court found that it was unnecessary to reach the First Amendment claims against the USPTO because it had already ruled in favor of the plaintiffs.

The lawsuit, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al., was filed on May 12 in the U.S. District Court for the Southern District of New York on behalf of breast cancer and women's health groups, individual women, geneticists and scientific associations representing approximately 150,000 researchers, pathologists and laboratory professionals.

Because the ACLU's lawsuit challenges the whole notion of gene patenting, its outcome could have far-reaching effects beyond the patents on the BRCA genes. Approximately 20 percent of all human genes are patented, including genes associated with Alzheimer's disease, muscular dystrophy, colon cancer, asthma and many other illnesses.

The court recognized the far-reaching impact of the case on medical research and public health. The opinion stated, "…the resolution of the issues presented to this Court deeply concerns breast cancer patients, medical professionals, researchers, caregivers, advocacy groups, existing gene patent holders and their investors, and those seeking to advance public health."

"The court correctly saw that companies should not be able to own the rights to a piece of the human genome," said Daniel B. Ravicher, Executive Director of PUBPAT and co-counsel in the lawsuit. "No one invented genes. Inventions are specific tests or drugs, which can be patented, but genes are not inventions."

The specific patents the ACLU had challenged are on the BRCA1 and BRCA2 genes. Mutations along the BRCA1 and 2 genes are responsible for most cases of hereditary breast and ovarian cancers. Many women with a history of breast and ovarian cancer in their families opt to undergo genetic testing to determine if they have the mutations on their BRCA genes that put them at increased risk for these diseases. This information is critical in helping these women decide on a plan of treatment or prevention, including increased surveillance or preventive mastectomies or ovary removal.

"We are extremely gratified by this groundbreaking decision," said Sandra Park, staff attorney with the ACLU Women's Rights Project. "This is the beginning of the end to patents that restrict women's access to their own genetic information and interfere with their medical care."

The patents granted to Myriad give the company the exclusive right to perform diagnostic tests on the BRCA1 and BRCA2 genes and to prevent any researcher from even looking at the genes without first getting permission from Myriad. Myriad's monopoly on the BRCA genes makes it impossible for women to access alternate tests or get a comprehensive second opinion about their results and allows Myriad to charge a high rate for their tests.

Several major organizations, including the American Medical Association, the March of Dimes and the American Society for Human Genetics, filed friend-of-the-court briefs in support of the challenge to the patents on the BRCA genes.

Attorneys on the case include Hansen and Aden Fine of the ACLU First Amendment Working Group; Park and Lenora Lapidus of the ACLU Women's Rights Project; and Ravicher and Sabrina Hassan of PUBPAT.

Today's decision can be found online at: www.aclu.org/free-speech-technology-and-liberty-womens-rights/association-molecular-pathology-et-al-v-uspto-et-al

More information about the case, including an ACLU video featuring breast cancer patients, plaintiff and supporter statements and declarations and the legal complaint, can be found online at: www.aclu.org/brca

Read more!

Get the facts about colorectal cancer!

"Get the facts about colorectal cancer," a CPTV town hall event is now available for viewing online. Our Director, Ellen Matloff, joins the panel ~1hr into the conversation to discuss hereditary colon cancer. Please click on the light blue link above to be directed to the video. Read more!

Our Spring 2010 Newsletter is Now Available!

Please click on the above light blue link to view our Spring 2010 Newsletter!

Read more!